Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

This study is testing a combination of two drugs — rituximab (a targeted antibody) and venetoclax (a targeted oral drug) — as a new front-line treatment for patients with marginal zone lymphoma (MZL), a slow-growing type of blood cancer, who have not previously received treatment for their lymphoma. **You may be eligible if...** - You have been diagnosed with marginal zone lymphoma (confirmed by biopsy) - You have measurable disease (at least one lymph node ≥1.5 cm or enlarged spleen) - If you have gastric MALT lymphoma, you are either H. pylori-negative or have already failed H. pylori eradication therapy - You have not received prior systemic treatment for MZL (some exceptions allowed) **You may NOT be eligible if...** - You have received prior rituximab or venetoclax treatment - Your MZL has transformed into a more aggressive lymphoma - You have significant heart, liver, or kidney problems - You have active, uncontrolled infections Talk to your doctor to see if this trial is right for you.